ERNA Ernexa Therapeutics (ERNA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000748592
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
4
13F, latest reported quarter
Ernexa Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Ernexa Therapeutics Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jun 9, 2025.
- -36.1% median (-26.3% mean) 90-day return after 3 previous buys.
- The trade is 59.0% of the 6,779,440 shares held after it.
- No other insider bought within 30 days.
- 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Cherington Charles bought about $2.0M of ERNA on Feb 10, 2026; 4 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Apr 2, 2025.
- -11.3% median (-11.3% mean) 90-day return after 2 previous buys.
- The trade is 51.0% of the 41,659,743 shares held after it.
- No other insider bought within 30 days.
- 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Cherington Charles bought about $2.1M of ERNA on Jun 9, 2025, the largest insider purchase at the company on our record; 4 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 2, 2022.
- The trade is 18.5% of the 20,401,602 shares held after it.
- No other insider bought within 30 days.
- 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Cherington Charles bought about $376.8K of ERNA on Apr 2, 2025, the largest insider purchase at the company since 2022; 4 funds added in the latest 13F quarter.17 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
4 funds bought in last quarter
below 97% of Pharma & Biotech
Revenue
+755.9% year over year
more than 95% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
1.6% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 71% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ERNA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-93.4%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ERNA: institutional holders (13F)
13F holdings, latest reported quarter
2,000,000 sh
$142.6K
15,104 sh
$100.4K
8,336 sh
$55.4K
6,000 sh
$39.9K
5,684 sh
$37.8K
Congress trades in ERNA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ERNA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ERNA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$58.9K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$37.8K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$25.5K position · as of 2026-05-31
0.0%
Blackstone Alternative Multi-Strategy Fund
$7 position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 4 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ERNA financials
Revenue growth
+755.9%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$582.0K
four quarters, 2024-01-01 to 2024-12-31
Revenue, TTM ERNA
| FY Dec 2025 | $582.0K |
| FY Dec 2024 | $582.0K |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | $5.8M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | $1.0K |
| Sep 2024 | $487.0K |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM ERNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -2,113% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -5,463% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM ERNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | -$16.2M |
| FY Dec 2023 | -$20.4M |
| FY Dec 2022 | -$21.3M |
| FY Dec 2021 | -$23.6M |
| Jun 2026 | -$4.2M |
| Mar 2026 | -$2.3M |
| Dec 2025 | -$1.2M |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$3.5M |
| Sep 2024 | -$6.3M |
At each fiscal year end
Single quarter
Debt to equity
0.64x
long-term 2020-12-31 (66 months older than the period end) plus current 2020-12-31 (66 months older than the period end); equity 2026-06-30
Debt to equity ERNA
| FY Dec 2025 | 0.85x |
| FY Dec 2024 | 1.19x |
| FY Dec 2023 | 0.91x |
| FY Dec 2022 | 0.17x |
| FY Dec 2021 | 0.08x |
| Jun 2026 | 0.64x |
| Mar 2026 | 0.30x |
| Dec 2025 | 0.85x |
| Sep 2025 | 0.57x |
| Jun 2025 | 0.46x |
| Mar 2025 | n/a |
| Dec 2024 | 1.19x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-4.35x
TTM operating cash flow over long-term 2020-12-31 (66 months older than the period end) plus current 2020-12-31 (66 months older than the period end)
Cash flow to debt ERNA
| FY Dec 2025 | -3.45x |
| FY Dec 2024 | -7.79x |
| FY Dec 2023 | -10.04x |
| FY Dec 2022 | -10.32x |
| FY Dec 2021 | -11.56x |
| Jun 2026 | -4.35x |
| Mar 2026 | -3.55x |
| Dec 2025 | -3.45x |
| Sep 2025 | -4.63x |
| Jun 2025 | -7.10x |
| Mar 2025 | -6.97x |
| Dec 2024 | -7.79x |
| Sep 2024 | -8.34x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-320.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ERNA
| FY Dec 2025 | -686.6% |
| FY Dec 2024 | -2,264% |
| FY Dec 2023 | -302.2% |
| FY Dec 2022 | -130.7% |
| FY Dec 2021 | -739.1% |
| Jun 2026 | -320.7% |
| Mar 2026 | -2,505% |
| Dec 2025 | -686.6% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -2,264% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-176.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ERNA
| FY Dec 2025 | -253.7% |
| FY Dec 2024 | -163.7% |
| FY Dec 2023 | -60.7% |
| FY Dec 2022 | -91.4% |
| FY Dec 2021 | -551.6% |
| Jun 2026 | -176.4% |
| Mar 2026 | -146.0% |
| Dec 2025 | -253.7% |
| Sep 2025 | -264.1% |
| Jun 2025 | -161.7% |
| Mar 2025 | -168.5% |
| Dec 2024 | -163.7% |
| Sep 2024 | -149.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital ERNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-331.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ERNA
| FY Dec 2025 | -368.9% |
| FY Dec 2024 | -69.8% |
| FY Dec 2023 | -73.9% |
| FY Dec 2022 | -156.4% |
| FY Dec 2021 | -604.5% |
| Jun 2026 | -331.4% |
| Mar 2026 | -1,427% |
| Dec 2025 | -368.9% |
| Sep 2025 | -1,106% |
| Jun 2025 | -48.7% |
| Mar 2025 | -69.1% |
| Dec 2024 | -69.8% |
| Sep 2024 | -92.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ERNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$883.9K
market value at close 2026-10-26 on 2026-08-06 shares, plus long-term 2020-12-31 (66 months older than the period end) plus current 2020-12-31 (66 months older than the period end), minus cash 2025-06-30
Enterprise value ERNA
| FY Dec 2025 | $233.2M |
| FY Dec 2024 | $5.6B |
| FY Dec 2023 | $3.6B |
| FY Dec 2022 | $3.5B |
| FY Dec 2021 | $1.6T |
| Jun 2026 | $5.5M |
| Mar 2026 | $143.5M |
| Dec 2025 | $233.2M |
| Sep 2025 | $208.7M |
| Jun 2025 | $2.9B |
| Mar 2025 | $3.5B |
| Dec 2024 | $5.6B |
| Sep 2024 | $2.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield ERNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | -0.3% |
| FY Dec 2023 | -0.6% |
| FY Dec 2022 | -0.6% |
| FY Dec 2021 | -0.0% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -4.6% |
| Jun 2025 | -0.5% |
| Mar 2025 | -0.4% |
| Dec 2024 | -0.3% |
| Sep 2024 | -0.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ERNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | n/a | $582.0K | $68.0K | $0 |
| Gross profit | n/a | $486.0K | -$168.0K | $0 |
| Operating income | -$9.3M | -$15.7M | -$21.1M | -$33.2M |
| Net income | -$14.1M | -$44.5M | -$21.7M | -$24.6M |
| EPS (diluted) | -2.24 | -48.96 | -4.08 | -8.06 |
| Operating cash flow | -$7.0M | -$15.8M | -$20.4M | -$21.0M |
| Cash | n/a | $1.7M | $7.6M | $11.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
ERNA Stock Sonar score 5/7 axes
Find similar shapesCompareERNA ranks highest on growth (95th percentile) and risk and compliance (81st), and lowest on institutional and government (3rd), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
